

Tymlos (abaloparatide) Prior Authorization Request Form Caterpillar Prescription Drug Benefit



Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION				
LAST NAME:	FIRST NAME:			
PHONE NUMBER:	DATE OF BIRTH:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
PATIENT INSURANCE ID NUMBER:				
MALE FEMALE HEIGHT (IN/CM): WEIGHT (LB/KG): ALLERGIES:				

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: <u>https://magellanrx.com/member/external/commercial/common/doc/en-us/phi_disclosure_authorization.pdf</u>

PRESCRIBER INFORMATION				
LAST NAME:	FIRST NAME:			
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:			
NPI NUMBER:	DEA NUMBER:			
PHONE NUMBER:	FAX NUMBER:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:			

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
NEW THERAPY		IF RENEWAL: DATE THERAPY INITIATED:			
DURATION OF THERAPY (SPECIFIC DATES):					

Continued on next page.







Tymlos (abaloparatide) Prior Authorization Request Form Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640



MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHER	MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) 🗌 NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
 Hypogonadal osteoporosis Idiopathic osteoporosis Osteoporosis associated with systemic glu Postmenopausal osteoporosis Other diagnosis:		AL INFORMATION TO SUPPORT A		
	ith Forteo (teriparatide)? 🗆 Yes 🗆 No			
Has the patient ever been treated with	a bisphosphonate? 🗆 Yes 🗆 No			
Does the patient have reflux/GERD OR	severe renal disease, as defined by a C	rCl less than 35 mL/min? *		
Does the patient have reflux/GERD OR severe renal disease, as defined by a CrCl less than 35 mL/min? * • Yes • No Has the patient failed previous treatment with at least one bisphosphonate (i.e., Fosamax [alendronate], Actonel [risedronate], Boniva [ibandronate], or Reclast [zoledronic acid]]? • Yes • No Has the patient been intolerant to previous treatment with at least one bisphosphonate (i.e., Fosamax [alendronate], Actonel [risedronate], Boniva [ibandronate], or Reclast [zoledronic acid]]? * • Yes • No Was the treatment failure measured by a decline in bone mineral density in g/cm2 of greater than or equal to 3% in the spine and/or hip while on bisphosphonate therapy? * • Yes • No Was the treatment failure due to a fracture while being treated with bisphosphonate therapy and did this fracture occur in the past 3 years?* • Yes • No * <i>Please provide documentation</i> . Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?				
 Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received. ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form. 				
rescriber Signature or Electronic I.D. Verification: Date: Date:				



Magella

ХX

MANAGEMENT



Tymlos (abaloparatide) Prior Authorization Request Form Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640



MEMBER'S LAST NAME:

MEMBER'S FIRST NAME:

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811



